布洛芬静脉注射制剂的开发与临床应用  

Development and clinical application of formulation of ibuprofen for intravenous

作　　者：李健和[1] 曹俊华[2] 易利丹[1,3] 谢双[1,3] 彭六保[1] 

机构地区：[1]中南大学湘雅二医院药学部,湖南长沙410011 [2]湖南省马王堆医院,湖南长沙410016 [3]中南大学药学院,湖南长沙410013

出　　处：《中国新药与临床杂志》2011年第8期584-587,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：非甾体类解热镇痛药大多为口服制剂,在口服困难的患者中存在很大的缺陷,2009年美国FDA首次批准上市了首个治疗疼痛和发热的布洛芬静脉注射制剂。本文介绍了布洛芬注射液的制剂开发、药理学、药动学、临床应用、不良反应以及与其他药物的相互作用等,供临床参考,以促进临床安全合理用药。Most of non-steroidal anti-inflammatory drugs （NSAIDs） are oral dosage forms which can＇t be administered when patients fail to take the drug orally. A formulation of ibuprofen for intravenous was approved by the US FDA for moderate to severe pain and for the reduction of fever. In this paper, the development of preparation, pharmacology, pharmacokinetics, clinical applications, adverse reactions, drug interactions, et al. of ibuprofen injection are reviewed in order to provide a reference for clinical applications and promote rational drug use.

关 键 词：布洛芬 制剂开发 药理学 药动学 临床试验 

分 类 号：R971.1[医药卫生—药品]